A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Overview of attention for article published in British Journal of Haematology, May 2009

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

patent: 10 patents

guideline: 1 clinical guideline source

Readers on

mendeley: 63 Mendeley

So far, Altmetric has seen 10 patents that reference this research output.

THERAPEUTIC T CELL PRODUCT

Application WO-2023198744-A1

World Intellectual Property Organisation (WIPO)

19 Oct 2023

TREATMENT OF LYMPHOMA

Application WO-2023104910-A1

World Intellectual Property Organisation (WIPO)

15 Jun 2023

CELL LINES FOR PRODUCING A RETROVIRAL VECTOR ENCODING A CAR

Application WO-2023072953-A1

World Intellectual Property Organisation (WIPO)

04 May 2023

VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS

Application WO-2022232797-A2

World Intellectual Property Organisation (WIPO)

03 Nov 2022

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 6 additional patents.